SOCS3 and endometrial cancer: Chen et al. [17] found that the methylation rate of SOCS3 in human endometrial cancer was 88.3%, which was significantly higher than that in complex endometrial hyperplasia (53.3%) and atypical hyperplasia (54.2%).